-+ 0.00%
-+ 0.00%
-+ 0.00%

Benchmark Maintains Buy on Biofrontera, Lowers Price Target to $2.75

Benzinga·05/19/2025 14:40:12
Listen to the news
Benchmark analyst Bruce Jackson maintains Biofrontera (NASDAQ:BFRI) with a Buy and lowers the price target from $7 to $2.75.